{"name":"Neumora Therapeutics, Inc.","slug":"neumora-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NMRA-335140","genericName":"NMRA-335140","slug":"nmra-335140","indication":"Major depressive disorder","status":"phase_3"}]}],"pipeline":[{"name":"NMRA-335140","genericName":"NMRA-335140","slug":"nmra-335140","phase":"phase_3","mechanism":"NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.","indications":["Major depressive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1fRkZHSE5YQ09OSWg1eGtRNDZzeW1yZ0JaQTdGNzdvY3hYR0N0aVNSTDNYMmdiX0pNYVNNZ1l0R0RJb1lzWTlaVUFMR3RwQV80TW04ZjdQZmNhSmxvYUNEWHhhZTF3U1F6SHQ3cHR3?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan","headline":"If You Invested $1,000 in Neumora Therapeutics Inc (NMRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOYzhIMDROUTVfZ1ROTEpraVhELWJDcW9oNnN2MGJpN1I1ejRPbF8yMnUwdUE3X2hOSXBUZGluRVJwdEVfZVp4SFZRSGpqSEpHNDRzSFFzazZUd09EQzBGcXV2TDR1em40TERERTEweGVtZ2lwSlE5TlhNN3cxOW5qbmI1RU53a05CYUlVYU5IR19LNXc5OUFQNjlSNDZhbnVIYmtTOWZCdF96TGtOQ2JJYm85Ym1vOE1wLTVrdzg3NWpndXp5X1RfaURPcjVnSGhVTXpvZWV0TjRVYUVJdmlJemM0ejA3Smp0d2R4T25XckY0Wmh3TDlYbC13WmYxZUxudDg2bnFoVFdjS0hMQjJHelR3cnYza0NOdWJoSFNjVFRUWmtXV1ZZ?oc=5","date":"2026-04-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (AN","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-11","type":"pipeline","source":"simplywall.st","summary":"Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st","headline":"Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-09","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st","headline":"3 Promising Penny Stocks With Market Caps Up To $400M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOeE5XbDlnMlA2NTljVWF1UUxjbWVkc0ZHTkNncHZvX1NQU1I5Tm1rVk16R0RCR0lqUnBMWnJyTzc3Y2hIUXV4ZFZhVWlVS3VYZEhfVXB4QXpBaFNfUVZ2dGZYWU9DekpfaGVaM2ZLem9MeUt4YUJyX25tSGxQQzI2d1g0VGRBLUsxSkFrWDh5LWZsZzZuRy1GXzMtQ2hYMlJQZzJKdTduMXVDREJCN0tBWUI5TzR0S3FlclZVSWpadHF3YkNRUkNlYlVjaVYwcng2b0JNRTZ0eTRQNTVjZkNqaWlmVWsyMGhyNjNfSGZMR2htVGdjbFZtd3lGU1JRU3NCdlNVRzI2VUlIeHN1MHpfVWUwUUUzOUt0aEludkRsYkZ0cVBkZUdESndaUTlKZk0?oc=5","date":"2026-01-06","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Neumora Therapeutics, Inc. (NMRA) and Arcellx Inc (ACLX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Neumora Therapeutics, Inc. (NMRA) and Arcellx ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPR2JfMlo2LUthMFFESW0zOE5LWERZUTZqNmpJd2prcm9rV0FYVEliWjVXY1ZLUXhZTTg5RmF0SmxWbXVhSTgtbTRFY2VQLThsS3ltZ3pyenl0T3pJaGhma1ZoWGRFaUVYZDRnYjNqTzhyWnlKWDExY0puM2JMemdOdmUzdDBaVzlzQ1B0ZDhVNTVBcEJsM2JEYktSR2EwbVZVSVdTMExIdFF2QzlkSlRVX0gtRE9MNFdBT1diNWhKd3A3blpUOHpISnFWYldjckE5T2NQcXlDSkNIc2NjNlhnWm9Kd0ZVck4tanZQZVNPRXFJZDU0a3VHN1gzVlVnLVc4Q1YzRzVNb3g?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire","headline":"Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNUlNCM3RoLTFKeXFLX0RtWlk4SHhEd3M4QUpqZzRBSkVkNmx3c3ZreVNZN1g5TEg2dzhMd3MyUkswMVJ5ZFEwU1o2aDZKTE9aQUpOYVFfUGo1b2RlNHExRlFQWWthRFo1Z2RiQVYxUjdtU01XeXNCUjRnSHRRTi1mVFB4LS1Jejg4Qko1TV9ZTV83MUN0dGZkOVZlWmI5TnljZ1E?oc=5","date":"2025-04-22","type":"pipeline","source":"BioPharma Dive","summary":"Former Neumora CEO to lead Galapagos spinout - BioPharma Dive","headline":"Former Neumora CEO to lead Galapagos spinout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPVGI2WHhKYVF2c2xFSFcteUdhcEJDMThfN1hLcFF6cUJMUUNlME9jeWRUN2R6d1JjNUZ1S0ladUZTem5iek9GbHo2OXVUcjVobXliSGN2MlowRlZjb1RqcmxuTUZJMmpPSlRuVGhLU3ZmcFNYZmVVb2FIZzFsNHlGYXFJSW1CN0NTc29Ya1VmWXQ3d1JBNmZFNDZDZGw4QW12cFFYaFRHenVoWjlFR3YybGo3b3R6cGdyaWRDMGJBTmxGZUplVVZEY0xhdlRPWmJCSE1DODNxNmVndw?oc=5","date":"2025-04-22","type":"pipeline","source":"Citeline News & Insights","summary":"Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO - Citeline News & Insights","headline":"Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zdnptN2gxMlBkY1p2MzU1aDFJQl9wUkt4WTQzSEx3VWlDNDIwZzUzYzFicTE3Umw0YWFUWHhGTi10czRKdm8tdzJTd3VMQ3lGanRuVjFuYVVrMVBu?oc=5","date":"2025-04-02","type":"pipeline","source":"TradingView","summary":"NMRA Stock Price and Chart — NASDAQ:NMRA - TradingView","headline":"NMRA Stock Price and Chart — NASDAQ:NMRA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNc2R3RnZLNzlLNEUyd1JEdXFsbExVVDh2bzVuLXBNa0V6Yk9STEJvSjcxTndMeno3Z19SRFpzLXVoMHpvVy0ybkhNVi1VeVk3Q0tJc2VvbGhDamg1eDJpV0VldHdoTmhSTEwwWFNaUDZLNjdMNTBtQWl4SHFyVHAxeEMtTDI5UFZTcDFSYWI5b0xLU1hYazIwS2RkNUhDQQ?oc=5","date":"2025-02-14","type":"trial","source":"Fierce Biotech","summary":"Neumora overhauls C-suite after phase 3 flop—Chutes & Ladders - Fierce Biotech","headline":"Neumora overhauls C-suite after phase 3 flop—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQaFEtaE5iOFBjbXZ4bVl2VUY3bS1VOEpLdWU5LVNsMlNUcWkwRTlCMmJHU3JYTFFDNlZuZjh1Ym5xNjdmeXIybG85Q0cwSmwwamlMUFRUbVViVlJoYTlmOW5wMzQyTXM4ZjJqVlk2YlBKOXlrV1dfN1RBdTMyT0luMW9xcjFQVzNxR2NHUTA3SlFWT0FwUFdFYmNyWncyUQ?oc=5","date":"2025-01-02","type":"trial","source":"BioPharma Dive","summary":"Neumora plummets on depression drug data - BioPharma Dive","headline":"Neumora plummets on depression drug data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNOHZxenBMMjlHM01qUzZsNHZNcTF6OFpELWRtYTZfVk4xbm13V2RHQlpmQkE1Zkx0NkducXJCMGhsOXcxZThybHRROTJodjEyUlduSG5MWXRJN3dSMmlOcDh1UnZCWEhNZGhxZ3lVeE5UaFcwOU40Q3U2V1RQYW9pbC1uYS1adDdQdEV3TGxtNkxtbHdXZGVQMFRSVQ?oc=5","date":"2025-01-02","type":"trial","source":"IndexBox","summary":"Neumora Therapeutics Shares Plummet After Depression Drug Trial Failure - News and Statistics - IndexBox","headline":"Neumora Therapeutics Shares Plummet After Depression Drug Trial Failure - News and Statistics","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}